People: CombiMatrix Corp (CBMX.W)

CBMX.W on CBOE When Trading NASDAQ Global Select Market

3.30USD
16 May 2013
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.30
Open
$3.27
Day's High
$3.30
Day's Low
$3.27
Volume
200
Avg. Vol
162
52-wk High
$13.27
52-wk Low
$2.88

Search Stocks

Summary

Name Age Since Current Position

R. Judd Jessup

 64 2013 Chairman of the Board

Mark McDonough

 43 2013 President, Chief Executive Officer, Director

Scott Burell

 47 2006 Chief Financial Officer, Treasurer, Secretary

Richard Hockett

 53 2013 Chief Medical Officer, Director

Jeremy Jones

 70 2012 Director

Richard Ding

 2012 Independent Director

Martin Felsenthal

 43 2011 Independent Director

Scott Gottlieb

 2009 Independent Director
» Insider Trading

Biographies

Name Description

R. Judd Jessup

 Mr. R. Judd Jessup is appointed as the Chairman of the Board of CombiMatrix Corp., effective March 12, 2013. He is no longer President, Chief Executive Officer, Director effective March 15, 2013. Mr. Jessup has over 35 years of experience in the healthcare and managed care industries. Most recently, he was Chief Executive Officer of US LABS, a national laboratory which provides cancer diagnostics and genetic testing services, from 2002 to 2005. He has background in the managed care industry having served as President of the Health Plans Division for FHP International from 1994 to 1996 as well as President of TakeCare, Inc., a publicly traded HMO operating in California, Colorado, Illinois and Ohio until it was sold to FHP. Mr. Jessup currently serves on the board of directors of Corvel Corporation, a publicly traded company. He served on the board of directors of NovaMed, Inc. from November 1998 until May 2011.

Mark McDonough

 Mr. Mark McDonough has been appointed as the President, Chief Executive Officer, Director of CombiMatrix Corporation, effective March 15, 2013. He came to CombiMatrix in 2012 with more than 15 years of experience in sales and business development with a specialty in diagnostics. McDonough previously worked for Fortune 500 companies (EMC and Lab Corp) as well as emerging companies (Ventana Medical Systems) and startups (Pathwork Diagnostics). Prior to Pathwork, from 2002-2008, McDonough worked for Irvine, CA-based USLabs/Dianon (when USLabs was acquired by LabCorp) and ultimately became Vice President of Sales. During his time there, he led a 56-member sales team, led various sales and marketing initiatives and helped drive a turnaround effort during a management overhaul. McDonough received a Bachelor’s Degree in Finance from Miami University in Oxford, Ohio.

Scott Burell

 Mr. Scott R. Burell is Chief Financial Officer, Treasurer and Secretary of CombiMatrix Corp. He has served as Chief Financial Officer since November 2006. Previously, he served as Vice President of Finance from November 2001 through November 2006, and as Controller from February 2000 through November 2001. From May 1999 to February 2001, Mr. Burell served as the Controller for Network Commerce, Inc., a publicly traded technology and infrastructure company located in Seattle. Prior to May 1999, Mr. Burell spent 9 years with Arthur Andersen's Audit and Business Advisory practice in Seattle. Mr. Burell is a certified public accountant in the state of Washington (currently inactive) and holds B.S. degrees in Accounting and Business Finance from Central Washington University. Mr. Burell is a member of the American Institute and Washington Society of Certified Public Accountants.

Richard Hockett

 Dr. Richard D. Hockett, Jr., M.D., is Chief Medical Officer, Director of CombiMatrix Corp. Prior to joining the company, Dr. Hockett was the Chief Medical Officer from March 2009 to April 2012 at Affymetrix, Inc., a genomic analysis tools company, where his responsibilities included applied genomics, new technology development, and regulatory affairs. From November 2008 to March 2009, Dr. Hockett was an independent consultant for Affymetrix. From 1999 to November 2008, Dr. Hockett was a Medical Fellow II, Group Leader for Genomic Medicine at Eli Lilly and Company, a pharmaceutical company. Dr. Hockett started his career as an Academic Pathologist in the Department of Pathology at the University of Alabama at Birmingham, where he oversaw the Clinical Immunology and Molecular Diagnostic Laboratories. Dr. Hockett is a board certified Clinical Pathologist, received his M.D. degree from the University of Minnesota and did his residency in Clinical Pathology at Washington University, St. Louis.

Jeremy Jones

 Mr. Jeremy M. Jones is appointed as the Director of CombiMatrix Corp. He is the Chairman of On Assignment, Inc., a publicly traded professional staffing firm, where he has served as a director since May 1995. Mr. Jones has been an investor and business development consultant since February 1998. From 1987 to 1995, Mr. Jones was Chief Executive Officer and Chairman of the Board of Homedco Group, Inc., a home healthcare services company, which became publicly traded in 1991. Homedco merged into Apria Healthcare Group, Inc. in 1995 and from 1995 through January 1998, Mr. Jones was Chief Executive Officer and Chairman of the Board of Apria Healthcare Group, Inc., which also provided home healthcare services. Mr. Jones served as Chairman of the Board of Byram Healthcare Centers, a provider of retail medical supplies and wholesale medical and hospital equipment, from February 1999 until its sale in March of 2008. Mr. Jones was a director for Access Point Medical from May 2004 to December 2005. Mr. Jones was a director of US Labs, an esoteric oncology and hematopathology laboratory from November 2003 through February 2005. From July 2003 to January 2011, Mr. Jones served as a director for Lifecare Solutions, Inc., a provider of integrated home healthcare products and services. Mr. Jones holds a bachelor’s degree in business administration from the University of Iowa.

Richard Ding

 Mr. Wei Richard Ding is Independent Director of CombiMatrix Corp. He is the Chief Executive Officer and a member of the board of directors of bioTheranostics Inc., a San Diego-based developer of molecular diagnostic tests and laboratory. Mr. Ding has been bioTheranostics' CEO since September 2008 and was the Vice President, Strategy and Business Development of France-based bioMerieux, a global company in the field of in vitro diagnostics from 2006 to 2008. Mr. Ding has also worked for Eli Lilly and Company, TenFold Corporation and Myriad Genetics, and is an active speaker and leader in the field of personalized medicine.

Martin Felsenthal

 Mr. Martin R. Felsenthal is Independent Director of CombiMatrix Corporation. Mr. Felsenthal also was appointed to the Compensation Committee of the Board. Mr. Felsenthal has been a Partner of HLM Venture Partners, a venture capital firm since 2007. Mr. Felsenthal was previously a General Partner of Salix Ventures, a venture capital firm, where he focused on investments in health care services and health care information technology. He joined Salix Ventures in 1997. Mr. Felsenthal served on the boards of Vantage Oncology, US Renal Care, Vericare, AccentCare, Titan Health and Payerpath. He is currently a director of Aperio Technologies, TelaDoc and Vericare Management. Mr. Felsenthal also serves on the Board of the Northern California Chapter of the Crohn's and Colitis Foundation of America. In addition, he completed the Chartered Financial Analyst program. He received a B.A. from Princeton University and an M.B.A. from the Stanford University Graduate School of Business.

Scott Gottlieb

 Dr. Scott Gottlieb, M.D., is Independent Director of CombiMatrix Corp. Dr. Gottlieb is currently a Resident Fellow at the American Enterprise Institute. Dr. Gottlieb is also a Clinical Assistant Professor at the NYU School of Medicine. From 2005 until 2007, Dr. Gottlieb served at the Food and Drug Administration ("FDA") as Deputy Commissioner for Medical and Scientific Affairs and before that, from 2003 until 2004, as Senior Advisor for Medical Technology to the FDA Commissioner and as the FDA's Director of Medical Policy Development. He left the FDA in the Spring of 2004 to work on implementation of the new Medicare Drug Benefit as a Senior Adviser to the Administrator of Medicare and Medicaid Services, where he supported the agency's policy work on quality improvement and coverage and payment decision-making, particularly related to new medical technologies. Dr. Gottlieb currently serves on the board of directors of Molecular Insight Pharmaceuticals. Dr. Gottlieb completed his residency in internal medicine at the Mount Sinai Hospital in New York City and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University in Connecticut.

Basic Compensation

Name Fiscal Year Total

R. Judd Jessup

 420,000

Mark McDonough

 --

Scott Burell

 325,006

Richard Hockett

 --

Jeremy Jones

 --

Richard Ding

 --

Martin Felsenthal

 --

Scott Gottlieb

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

R. Judd Jessup

 0 0

Mark McDonough

 0 0

Scott Burell

 0 0

Richard Hockett

 0 0

Jeremy Jones

 0 0

Richard Ding

 0 0

Martin Felsenthal

 0 0

Scott Gottlieb

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks